Osteosarcoma, characterized by its aggressive nature and propensity for metastasis, remains a formidable challenge in oncology. Traditional treatment modalities, including surgery and chemotherapy, have not significantly improved long-term survival rates for patients, especially those with advanced disease. The introduction of immunotherapy has revolutionized cancer treatment; however, its effectiveness in osteosarcoma has been limited. This limitation has spurred researchers to investigate novel combinations and strategies that may synergistically enhance the immune response against tumors.

At the heart of the study is the role of OxLDL, a modified form of low-density lipoprotein, in influencing the tumor microenvironment. OxLDL is known to play a significant role in atherosclerosis, but its implications in cancer biology have garnered increasing attention. The research team aimed to elucidate how OxLDL interacts with CAFs, a critical component of the tumor stroma that is known to promote tumor growth and immune evasion. By focusing on the CD36 receptor, which is abundantly expressed on CAFs, the researchers sought to uncover a pathway that could be harnessed for therapeutic benefit.

The findings revealed that OxLDL significantly reprograms CD36+ CAFs, leading to a more immune-suppressive tumor microenvironment that hampers the efficacy of PD-1 inhibitors. PD-1 therapy, designed to unleash the immune system against cancer cells, becomes less effective in the presence of these altered CAFs. By understanding the mechanisms through which OxLDL influences CAF activity, the scientists identified a target for intervention that could reverse this immune suppression.

A pivotal aspect of the study is the demonstration that targeting OxLDL-mediated reprogramming of CAFs enhances the therapeutic impact of PD-1 inhibitors. When the researchers combined OxLDL-targeting strategies with PD-1 immunotherapy in preclinical models, they observed a significant improvement in anti-tumor immune responses. This combination therapy not only bolstered the efficacy of PD-1 inhibitors but also reprogrammed the CAFs back toward a more tumor-restrictive phenotype, thereby creating a more favorable environment for immune activation.

The implications of these findings extend beyond osteosarcoma. The interplay between OxLDL, CAFs, and immune modulation may be relevant to other forms of cancer where CAFs play a critical role in supporting tumor growth and immune evasion. As the research community seeks to optimize existing immunotherapies, understanding the biochemical and cellular interactions within the tumor microenvironment will be paramount in developing more effective treatment strategies.

Moreover, this study underscores the need for a multidisciplinary approach in cancer research. The intersection of immunology, lipid metabolism, and cancer biology provides a fertile ground for innovations that could transform patient outcomes. By targeting the metabolic aspects of tumor biochemistry, researchers are paving the way for novel therapeutic avenues that could enhance the effectiveness of immunotherapeutic agents across different cancer types.

Translating these promising preclinical findings into clinical applications will be an essential next step. Clinical trials assessing the safety and efficacy of combining OxLDL-targeting strategies with PD-1 immunotherapy in osteosarcoma patients will be crucial in determining whether this approach can translate into improved survival rates and quality of life for patients facing this challenging disease. Continued collaboration between basic scientists and clinical oncologists will be vital in navigating the complexities of cancer treatment and ensuring that groundbreaking discoveries reach the clinic.

In conclusion, the research conducted by Zeng and colleagues represents a significant advancement in our understanding of the tumor microenvironment in osteosarcoma. By highlighting the role of OxLDL in modulating CAF function and its impact on PD-1 immunotherapy, this study opens new avenues for enhancing cancer treatment. As we stand on the brink of a new era in oncology, harnessing the complexities of the immune system and tumor biology will be fundamental in the fight against cancer and improving patient outcomes.

The challenge now lies in the implementation of these findings in clinical settings, where the complexities of human biology and tumor heterogeneity must be navigated. The journey from bench to bedside is often fraught with obstacles, but the potential for improved therapies that can reshape the prognosis for osteosarcoma patients is an endeavor well worth pursuing. This research serves as a beacon of hope, emphasizing the importance of innovation and collaboration in the relentless pursuit of effective cancer therapies.

Research continues to uncover the intricate pathways that connect metabolism and immunity, and this study is a testament to the power of scientific inquiry in unraveling these connections. The future of cancer treatment may very well depend on our ability to understand and manipulate these pathways, providing a glimmer of hope for millions affected by various types of cancer around the world. It is through such innovative approaches that the goal of more effective, personalized cancer therapies can be achieved.

As the complexities of cancer treatment continue to evolve, the findings from this research remind us of the importance of maintaining a multifaceted approach to combating this diseases. The integration of immunotherapy with novel targets such as OxLDL may represent a paradigm shift that enhances the effectiveness of existing treatments and ultimately leads to better outcomes for patients. With ongoing research and unwavering dedication, the cancer research community remains poised to tackle some of the most significant challenges in the field, bringing hope to those affected by this relentless disease.

Subject of Research: Targeting OxLDL-mediated CD36+ CAF reprogramming to enhance PD-1 immunotherapy in osteosarcoma.

Article Title: Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma.

Article References: Zeng, A., Chen, H., Luo, T. et al. Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma. Mol Cancer 25, 14 (2026). https://doi.org/10.1186/s12943-025-02516-2

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12943-025-02516-2

Keywords: Osteosarcoma, OxLDL, CD36, CAF, PD-1 immunotherapy, tumor microenvironment, cancer therapy, immunology, lipid metabolism.

At the core of this research lies the recognition that the tumor microenvironment is not merely a passive backdrop to cancer progression but a dynamic entity that significantly influences tumor behavior and treatment response. In lung adenocarcinoma, the infiltration of immune cells often reflects a war between tumor evasion tactics and the patient’s immune response. The pivotal question that emerged was how certain fibroblast populations, particularly those expressing the CLEC3B marker, play a role in reprogramming the immune microenvironment. The study provided insights into how these fibroblasts contribute to an immunosuppressive niche that promotes tumor growth while concurrently influencing therapeutic efficacy.

The methodology employed in this research is noteworthy. By integrating single-cell transcriptomics with spatial profiling techniques, the researchers created a robust framework for characterizing the tumor microenvironment at an unprecedented resolution. This approach allowed them to isolate distinct populations of cells within the tumor stroma and assess their functional states in relation to various tumor and immune cells. The ability to visualize these interactions in situ represents a significant advancement in cancer biology, enabling researchers to track changes in cellular interactions and molecular signaling pathways over time.

The findings underscore the importance of CLEC3B-positive iCAFs in lung adenocarcinoma. These fibroblasts are implicated in the secretion of cytokines and growth factors that profoundly affect immune cell behavior. Instead of merely supporting tumor structure, these cells can actively modulate the immune response, promoting an environment conducive to tumor survival and growth. The researchers highlighted that understanding these mechanisms is crucial for enhancing the response to current immunotherapies, particularly in cases where patients exhibit limited clinical benefits from existing treatment protocols.

Furthermore, the research examined how the presence of these iCAFs correlates with patient outcomes. By analyzing comprehensive datasets from multiple cancer types, they found a consistent pattern where high levels of CLEC3B expression correlated with poor prognosis. These results suggest that targeting these specific fibroblast populations might not only improve patient outcomes but could also provide a novel therapeutic avenue, redirecting the focus of immunotherapy from solely attacking tumor cells to also dismantling the supportive infrastructure that aids their survival.

The implications of this study extend beyond lung adenocarcinoma. By employing a pan-cancer perspective, the researchers have laid the groundwork for exploring similar fibroblast populations in other malignancies. This broad approach allows for a deeper understanding of the tumor-associated microenvironment across various cancer types, promoting the potential for discovering universal biomarkers that could enhance the predictive capability of oncologists when devising treatment plans. The shared mechanisms across different tumors could illuminate new therapeutic strategies that leverage the tumor stroma rather than solely targeting the cancer cells themselves.

In addition to enhancing immunotherapy effectiveness, the study raises critical questions regarding the timing and combination of therapeutic interventions. Understanding the dynamics of CLEC3B-positive iCAFs and their interactions with other immune cells and tumor cells may guide the design of sequential or combinatorial therapy regimens. For instance, introducing agents that target these fibroblasts ahead of conventional therapy could sensitize tumors to immunotherapeutic agents, potentially overcoming resistance mechanisms that lead to treatment failure.

The researchers acknowledge the complexity inherent in targeting the tumor microenvironment. Unlike traditional cancer therapies that focus solely on the cancer cell, targeting stromal components requires a nuanced understanding of cellular interactions and signaling pathways. Future clinical trials will need to carefully evaluate the impact of fibroblast-targeting therapeutics on the broader immune context, ensuring that we do not inadvertently induce adverse effects that could compromise patient safety.

Despite the promising nature of this study, the authors also noted the considerable obstacles that remain. Translating the insights gained from spatially resolved transcriptomics into clinical practice demands extensive further research. There is a need to verify the results in larger cohorts and to investigate longitudinal changes that occur within the tumor microenvironment in response to treatment. Additionally, the development of specific inhibitors or modulators of CLEC3B+ iCAFs must be a priority, followed by rigorous preclinical and clinical testing to ensure their efficacy and safety.

As we step into an era defined by personalized medicine, the findings from this research play a pivotal role in shaping the future of cancer therapy. The integration of advanced molecular techniques and the focus on the tumor microenvironment could redefine our understanding of cancer biology and treatment. With ongoing advancements and collaborations in biomedical research, the community is closer than ever to unraveling the complexities of tumors and their microenvironments.

In summary, the exploration of CLEC3B+ iCAFs provides critical insights into the tumor microenvironment’s role in lung adenocarcinoma and highlights the need for innovative strategies that target both tumors and their accompanying fibroblast populations. As researchers continue to decode the intricate relationships within the tumor stroma, targeted therapies holding the promise of improved therapeutic responses may soon emerge, making the dream of effective cancer treatment a reality for many patients.

The future of lung adenocarcinoma therapy may very well hinge on these findings. As the research community rallies around this new understanding of fibroblast biology, we anticipate that their work will not only impact lung cancer treatment but will stimulate new scientific inquiries across various cancer types. This knowledge may ultimately pave the way for next-generation therapies that take advantage of the complex interactions within the tumor microenvironment, redefining how we approach cancer in the 21st century.

In conclusion, the work done by Li, S., Weng, K., and Yan, L. broadens our understanding of the tumor microenvironment, particularly in the context of lung adenocarcinoma. Their meticulous research offers a new perspective on fibroblast biology, particularly CLEC3B-positive inflammatory cancer-associated fibroblasts, illuminating pathways that could significantly enhance the efficacy of current treatments and open up avenues for novel therapies. This study is a testament to the potential that lies within the intersection of cancer research and immunotherapy, heralding a new chapter in the journey toward effective cancer management.

Subject of Research: Tumor microenvironment remodeling in lung adenocarcinoma.

Article Title: Decoding the tumor microenvironment remodeling orchestrated by CLEC3B+ inflammatory cancer-associated fibroblasts in lung adenocarcinoma immunotherapy: elucidation from pan-cancer spatially single-cell transcriptomics landscape.

Article References:

Li, S., Weng, K., Yan, L. et al. Decoding the tumor microenvironment remodeling orchestrated by CLEC3B+ inflammatory cancer-associated fibroblasts in lung adenocarcinoma immunotherapy: elucidation from pan-cancer spatially single-cell transcriptomics landscape.
J Transl Med (2026). https://doi.org/10.1186/s12967-026-07677-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-07677-2

Keywords: tumor microenvironment, lung adenocarcinoma, CLEC3B, inflammatory cancer-associated fibroblasts, immunotherapy, single-cell transcriptomics, cancer therapy.

The extracellular matrix (ECM) is a crucial component of the TME, and collagen comprises approximately 90% of this scaffold. Excessive collagen deposition not only mechanically fortifies tumors but also forms a formidable physical barrier against immune surveillance and pharmacologic intervention. Central to collagen’s structural integrity is glycine, the most abundant amino acid within its triple-helix configuration, yet the mechanisms ensuring sufficient glycine supply in the tumor milieu remained elusive until now. Recent scientific investigations have illuminated a pivotal metabolic shift in CRC-associated fibroblasts, whereby de novo glycine synthesis drives enhanced collagen production, aggressively remodeling the ECM to favor cancer progression.

To dissect this phenomenon, researchers isolated primary fibroblast populations from human colorectal tumors and adjacent normal tissues, establishing cultures of CAFs and normal fibroblasts (NFs) for comparative analysis. Metabolomic profiling of these cells revealed a pronounced reprogramming in amino acid metabolism specific to CAFs. Notably, glycine concentrations were nearly doubled within these activated fibroblasts compared to their normal counterparts, a finding corroborated by elevated glycine levels in conditioned media derived from CAF cultures. Intriguingly, this glycine augmentation was attributed predominantly to heightened endogenous synthesis rather than extracellular uptake, directing attention toward the enzymatic machinery governing this pathway.

Further molecular characterization uncovered that the glycine biosynthetic pathway enzymes—phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1), phosphoserine phosphatase (PSPH), and serine hydroxymethyltransferase 2 (SHMT2)—were upregulated at both transcriptional and protein levels in CAFs. These findings reflect a coordinated enhancement of the serine-glycine pathway, enabling sustained production of glycine to meet the biosynthetic demands of collagen assembly. PHGDH, catalyzing the rate-limiting step of this pathway, emerged as a particularly critical enzyme, linking metabolic reprogramming to structural ECM remodeling.

Delving into the signals orchestrating this metabolic remodeling, the study leveraged conditioned media from aggressive SW480 colorectal cancer cells and identified a soluble factor responsible for modulating fibroblast metabolism. Transforming growth factor-beta 1 (TGF-β1), a cytokine well known for its multifaceted roles in tumor biology, was secreted at substantially higher levels by CRC cells relative to CAFs. Treatment of fibroblasts with exogenous TGF-β1 recapitulated the metabolic activation seen with cancer cell-conditioned media, including upregulation of glycine synthesis enzymes and increased collagen production. Conversely, pharmacologic blockade of TGF-β signaling via the receptor I inhibitor SB431542 or neutralizing antibodies abrogated these effects, firmly establishing TGF-β1 as the linchpin in this cross-talk.

The therapeutic implications of these findings are significant. With PHGDH positioned at the nexus of this metabolic axis, the authors explored the potential of targeting this enzyme to disrupt collagen overproduction in CAFs and thereby modulate the tumor microenvironment. Both RNA interference-mediated knockdown and selective pharmacological inhibition using NCT503 substantially diminished TGF-β1-induced collagen I and IV synthesis. Western blot and immunofluorescence analyses confirmed the downregulation of these critical ECM components, indicating that PHGDH inhibition can effectively incapacitate the metabolic support system CAFs utilize to reinforce tumor infrastructure.

The relevance of these discoveries extends beyond in vitro cultures to human colorectal cancer tissues. Employing histological techniques such as Masson’s trichrome staining and immunohistochemistry, the study demonstrated robust collagen I/IV deposition co-localizing with elevated PHGDH expression and CAF marker alpha-smooth muscle actin (α-SMA) in tumor specimens compared to normal adjacent tissues. These in situ observations affirm the clinical significance of metabolic remodeling in the tumor stroma and underscore PHGDH as a viable biomarker and therapeutic target.

To further substantiate their findings, the research team analyzed public datasets derived from CRC patient samples and associated stromal populations. Dataset PRJNA717755 and PRJNA319481 revealed positive correlations between expression levels of TGF-β receptor I (TGF-βR1), enzymes involved in de novo glycine synthesis, and collagen gene expression. This convergence of bioinformatics, biochemical assays, and pathology affirms a conserved regulatory axis driving ECM remodeling through metabolic manipulation in CRC.

Taken together, this comprehensive study elucidates a novel mechanism by which colorectal cancer cells manipulate their microenvironment to foster tumor progression and resistance. By secreting TGF-β1, cancer cells induce a metabolic shift in CAFs, activating de novo glycine synthesis pathways that support excessive collagen production. This not only structurally remodels the tumor stroma but also contributes to the pathophysiology of CRC by establishing a protective niche that impairs immune infiltration and drug efficacy.

Importantly, the identification of PHGDH as a central mediator offers a promising avenue for therapeutic intervention. Inhibitors targeting this metabolic enzyme have the potential to dismantle the tumor-supportive ECM by curtailing glycine-dependent collagen synthesis, thereby attenuating tumor aggressiveness and possibly enhancing responsiveness to existing treatments. This approach signifies a paradigm shift, moving beyond targeting cancer cells alone to incorporating strategies aimed at stromal metabolism and ECM dynamics.

Future investigations may explore the combinational potential of PHGDH inhibitors with immune checkpoint blockers or chemotherapies to overcome the physical and immunosuppressive barriers imposed by the collagen-rich TME. Moreover, expanding this research to diverse tumor types could unveil broader applications for targeting amino acid metabolism in CAFs. The elucidation of such metabolic crosstalk reinforces the importance of understanding tumor-stroma interactions and heralds a new frontier in cancer therapeutics.

In summary, this groundbreaking research unravels the complex interplay between colorectal cancer cells and their microenvironment, emphasizing the crucial role of de novo glycine synthesis in CAF-mediated collagen production. Through meticulous biochemical and histological analyses complemented by bioinformatics, the study lays a robust foundation for exploiting metabolic pathways as therapeutic targets. Targeting PHGDH in CAFs emerges as a compelling strategy to disrupt tumor-stroma communication, dismantle the collagenous fortress safeguarding tumor cells, and improve clinical outcomes in colorectal cancer.

Subject of Research: Metabolic reprogramming of cancer-associated fibroblasts to support collagen synthesis in colorectal cancer via de novo glycine synthesis induced by tumor-derived TGF-β1.

Article Title: Colorectal Cancer Cells Drive Collagen Production in Cancer-Associated Fibroblasts via TGF-β1-Induced de novo Glycine Synthesis: PHGDH as a Promising Therapeutic Target

News Publication Date: 24-Aug-2025

Web References: http://dx.doi.org/10.1002/mog2.70037

Image Credits: Yinglan Zhao & Xiao Du

Keywords: Colorectal cancer, cancer-associated fibroblasts, extracellular matrix, collagen synthesis, glycine metabolism, de novo glycine synthesis, phosphoglycerate dehydrogenase (PHGDH), transforming growth factor-beta 1 (TGF-β1), tumor microenvironment, metabolic reprogramming, therapeutic target, fibrosis

Oral submucous fibrosis (OSF), a potentially malignant disorder frequently linked to areca nut chewing, predisposes patients to a particular subtype of OSCC known as ODSCC (oral squamous cell carcinoma derived from OSF). This particular lineage of cancer cells appears to create a more hostile and immune-evasive microenvironment, setting it apart from OSCCs without OSF history (termed NODSCC). While previous studies have evaluated the molecular and metabolic landscapes of ODSCC, the precise cellular players driving the immunosuppressive network remained elusive until now.

Employing state-of-the-art single-cell RNA sequencing (scRNA-seq) coupled with spatial transcriptomics (ST) techniques, Zhao and colleagues performed a deep dissection of the tumor microenvironment (TME) in ODSCC. By analyzing publicly available GEO database datasets alongside multiple immunofluorescence staining, they delineated the complex cellular crosstalk that supports tumor progression and immune evasion. Their findings indicate a pivotal elevation of exhausted CD8+ T cells and regulatory T cells (Tregs), which suppress effective anti-tumor immunity, paired with a marked reduction in cytotoxic T lymphocytes — the frontline soldiers of tumor eradication.

A critical discovery within this study is the enrichment of macrophages expressing Inhibin subunit beta A (INHBA), termed INHBA+ macrophages, which are prominently elevated in ODSCC compared to NODSCC. These macrophages display the strongest immune suppressive signatures, including heightened immune checkpoint molecule activity, diminished major histocompatibility complex (MHC) expression, and increased levels of SPP1, a marker closely associated with tumor-promoting functions. Importantly, INHBA+ macrophages sourced from ODSCC exhibit more pronounced immunosuppressive properties than those from NODSCC, suggesting a microenvironment finely tuned to thwart immune surveillance.

Alongside these macrophages, the study identified proinflammatory cancer-associated fibroblasts (iCAFs) as another major contributor to the unique tumor ecology of ODSCC. These iCAFs express higher levels of INHBA, while also being enriched in pathways related to immune modulation and extracellular matrix remodeling. Crucially, iCAFs in ODSCC express genes like TDO2, IDO1, and DUSP4 at significantly elevated levels compared to NODSCC. These genes are implicated in creating an immunosuppressive microenvironment through the catabolism of tryptophan and immune signaling regulation, collectively dampening the immune system’s ability to attack tumor cells effectively.

The researchers also spotlighted how INHBA expression is not only prevalent within immune and stromal cells but can be induced by arecoline, a principal alkaloid found in areca nuts frequently chewed in regions endemic to OSF. In vitro experiments utilizing THP-1 macrophage-like cells demonstrated that arecoline stimulation dramatically increases INHBA expression. This result bridges a direct causative link between lifestyle risk factors and molecular changes underpinning tumor immune evasion.

Integration of spatial transcriptomics revealed a localized co-distribution of INHBA+ macrophages, iCAFs, and Tregs within the TME. This physical proximity suggests that these cell subsets engage in intimate paracrine interactions that sculpt an immunosuppressive niche. Further computational analyses pinpointed specific molecular interactions involving INHBA and its receptors ACVR1, ACVR2A, and ACVR2B in regions where these immune and stromal cells converge, inferring a potential signaling axis modulating Treg differentiation and functional activity.

From a translational perspective, the heightened presence of INHBA+ macrophages and iCAFs in ODSCC likely manifests as a more severe tumor immunosuppressive microenvironment (TISME), which could explain why patients with this subtype show poorer responses to immune checkpoint blockade therapies. This insight not only emphasizes the need to customize immunotherapy regimens considering tumor origin and microenvironment but also identifies INHBA and its associated signaling pathways as promising therapeutic targets.

The comprehensive multi-omics approach deployed in this study underscores the necessity of understanding tumor biology at a single-cell resolution, particularly within spatial contexts. By navigating the complex heterogeneity of tumor-infiltrating immune and stromal cells, the researchers have illuminated a heretofore unappreciated architectural framework of the ODSCC microenvironment that confers immune privilege and supports cancer progression.

Outside of immune evasion, the enhanced expression of collagen and extracellular matrix components orchestrated by iCAFs suggests these fibroblasts also contribute to the physical remodeling of the tumor niche, which may further impede immune cell infiltration. This combination of biochemical and biomechanical immunosuppressive modalities paints a sophisticated portrait of tumor-host interactions in OSF-related OSCC.

Furthermore, the coupling of environmental exposure (arecoline) to molecular shifts within the TME highlights the multifaceted drivers of tumor evolution in specific populations. This offers crucial insights for preventative interventions aimed at diminishing OSF incidence, potentially reducing subsequent malignancies with refractory immune microenvironments.

Beyond its immediate clinical relevance, the study opens new avenues for mechanistic exploration of TGF-β family signaling, given INHBA’s role as a member of this superfamily. Understanding how INHBA-ACVR receptor complexes specifically modulate immune cell phenotypes may reveal novel checkpoints for modulating immunosuppression that can be pharmacologically exploited in OSCC and other solid tumors.

In summary, this pioneering research delineates a richly detailed immune-stromal landscape in ODSCC defined by INHBA+ macrophages and pro-inflammatory CAFs that foster a uniquely suppressive microenvironment. The findings not only deepen comprehension of OSF-derived OSCC pathobiology but also carry impactful translational implications for biomarker development and rational design of combination therapies targeting the immunosuppressive network.

As immunotherapy continues to transform oncology, studies like Zhao et al.’s serve as a reminder that the microenvironment’s cellular choreography can decisively influence treatment outcomes. By unraveling the complexity of tumor-immune crosstalk in OSF-related cancers, science edges closer to therapies tailored to surmount immune escape and improve prognosis for patients burdened by this challenging disease.

—

Subject of Research: Distinctive immunosuppressive tumor microenvironment in submucous fibrosis-derived oral squamous cell carcinoma characterized by INHBA-positive macrophages and pro-inflammatory cancer-associated fibroblasts.

Article Title: INHBA⁺ macrophages and Pro-inflammatory CAFs are associated with distinctive immunosuppressive tumor microenvironment in submucous Fibrosis-Derived oral squamous cell carcinoma

Article References:
Zhao, S., Zhang, Y., Meng, X. et al. INHBA⁺ macrophages and Pro-inflammatory CAFs are associated with distinctive immunosuppressive tumor microenvironment in submucous Fibrosis-Derived oral squamous cell carcinoma. BMC Cancer 25, 857 (2025). https://doi.org/10.1186/s12885-025-14261-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14261-2

For years, Galectin-1, a member of the lectin family known for its carbohydrate-binding properties, has been implicated in tumor progression due to its secretion by stromal fibroblasts, where it promotes immune evasion, angiogenesis, and matrix remodeling. However, until now, the intracellular functions of this molecule, particularly inside fibroblast nuclei, had remained largely unexplored. The recent findings published in the Proceedings of the National Academy of Sciences (PNAS) mark a paradigm shift by demonstrating that nuclear Galectin-1 exerts precise epigenetic control over gene expression programs that drive fibroblast activation, which in turn supports pancreatic tumor progression. This discovery elucidates a novel layer of tumor-stroma crosstalk that may open new therapeutic avenues.

Dr. Pilar Navarro, the coordinator of the Cancer Molecular Targets Research Group at the Hospital del Mar Research Institute and a leading figure in this investigation, explains that the stroma’s notorious role in pancreatic ductal adenocarcinoma (PDAC) aggressiveness hinges on the multifarious functions of fibroblasts. These cells not only secrete factors enhancing tumor cell survival and proliferation but also establish a physical barrier that impedes drug delivery. Importantly, fibroblasts’ secretion of Galectin-1 was known to contribute to these malignant attributes. “Our research reveals that Galectin-1 is not simply secreted into the tumor microenvironment, but it is also localized within the nuclei of stromal fibroblasts, where it functions as a critical regulator of gene expression,” Dr. Navarro remarks, highlighting the dual roles of the protein.

The team conducted comprehensive molecular analyses on pancreatic tumor tissue samples obtained from patients, confirming the nuclear presence of Galectin-1 in stromal fibroblasts in situ. Subsequently, cultured human fibroblast lines were utilized for mechanistic studies, revealing that nuclear Galectin-1 modulates specific gene networks through epigenetic mechanisms, such as histone modification or chromatin remodeling—processes that alter gene expression without changing the underlying DNA sequence. Notably, one of the most significant targets under the regulatory control of nuclear Galectin-1 is the oncogene KRAS, a canonical driver mutated in over 90 percent of PDAC cases and instrumental in promoting cancer cell proliferation and survival.

The regulation of KRAS expression inside fibroblasts is an unprecedented finding, suggesting that fibroblasts may adopt tumor-promoting phenotypes via intracellular signaling pathways converging on KRAS activation. Unlike the mutant version of KRAS in cancer cells, the fibroblast KRAS is wild-type but is upregulated by nuclear Galectin-1, thereby enhancing the supportive role fibroblasts play in tumor development. “This sheds light on a complex, reciprocal relationship wherein fibroblasts not only respond to tumor signals but also actively contribute to sustaining oncogenic programs,” elaborates Dr. Navarro.

These insights pave the way for therapeutic strategies targeting not only the extracellular effects of Galectin-1 but also its newly identified intracellular functions. Dr. Neus Martínez-Bosch, a researcher involved in the project, emphasizes this point, stating, “Previous attempts to inhibit Galectin-1 aimed at blocking the protein secreted by stromal cells. Our results suggest that to effectively disrupt fibroblast-tumor interactions, inhibitors must penetrate the fibroblast nucleus and inhibit Galectin-1’s gene regulatory activities.” Consequently, drug development efforts now face the challenge of identifying molecules capable of entering stromal fibroblasts and precisely modulating nuclear Galectin-1 activity.

To validate the therapeutic potential of targeting nuclear Galectin-1, scientists employed genetic and pharmacological methods to inhibit the protein and KRAS gene expression in cultured fibroblasts. The resultant effects were profound: fibroblast activation was attenuated, leading to a significant decrease in their capacity to sustain malignant behaviors in tumor cells. This evidence strongly supports the concept that disrupting the intracellular axis governed by Galectin-1 may impair the supportive stromal response essential for pancreatic cancer progression.

Dr. Judith Vinaixa, the study’s first author, underscores the breadth of gene expression regulation mediated by nuclear Galectin-1, noting the protein’s influence over multiple gene sets critical for controlling fibroblast behavior. Such multifactorial control mechanisms point to Galectin-1 as a master regulator within the tumor stroma, orchestrating complex epigenetic landscapes that facilitate cancer’s invasive and drug-resistant nature. The diverse roles of Galectin-1 suggest that its inhibition may yield pleiotropic antitumor effects beyond simply reducing fibroblast activation.

Complementing these findings, Dr. Gabriel Rabinovich, a co-investigator from IBYME (CONICET) and the CaixaResearch Institute, highlights the broader implications of Galectin-1 inhibition. Besides its fibroblast-nuclear functions, Galectin-1 contributes to angiogenesis and immune modulation within the tumor milieu, including resistance mechanisms against immunotherapies. Therefore, combined blockade of extracellular and intracellular Galectin-1 activities could synergistically impair tumor growth by both disrupting stromal support and enhancing immune-mediated tumor clearance. This multifaceted approach positions Galectin-1 as a highly promising target in the fight against pancreatic cancer, a disease urgently needing innovative therapeutic interventions.

The collaborative nature of this study, incorporating pathology experts from Hospital del Mar and cancer research specialists from CIBERONC, underscores the multidisciplinary effort required to unravel the complexities of the pancreatic tumor microenvironment. Their joint expertise facilitated the integration of histological evaluation with molecular biology and epigenetics, strengthening the validity and clinical relevance of the findings.

As the field moves forward, future research will inevitably focus on drug discovery tailored to inhibit nuclear Galectin-1, optimizing delivery systems to achieve efficient intracellular targeting in fibroblasts. Moreover, combination therapies that simultaneously target extracellular Galectin-1 and other tumor-promoting pathways could revolutionize treatment paradigms for pancreatic cancer. These innovative approaches stand to overcome one of the most formidable hurdles in oncology by dismantling the protective tumor stroma and restoring therapeutic efficacy.

Ultimately, this landmark study redefines our understanding of the pancreatic tumor microenvironment by spotlighting a novel nuclear function of Galectin-1 within stromal fibroblasts. The findings not only deepen the biological comprehension of stromal-tumor interactions but also open promising new pathways for the development of targeted therapies, giving hope to patients suffering from one of the deadliest cancers known today.

Subject of Research: Nuclear functions of Galectin-1 in pancreatic cancer-associated fibroblasts and its role in tumor progression

Article Title: Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells

News Publication Date: 15th April 2025

Web References:
https://doi.org/10.1073/pnas.2424051122

References:
Vinaixa J, Martínez-Bosch N, Gibert J, Manero-Rupérez N, Santofimia-Castaño P, Baudou FG, Vera RE, Pease DR, Iglesias M, Sen S, Wang X, Almada LL, Marks DL, Moreno M, Iovanna JL, Rabinovich GA, Fernandez-Zapico ME, Navarro P. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Proc Natl Acad Sci U S A. 2025 Apr 8;122(14):e2424051122. doi: 10.1073/pnas.2424051122. Epub 2025 Apr 2. PMID: 40172967.

Keywords: Pancreatic cancer, tumor microenvironment, stroma, fibroblasts, Galectin-1, nuclear proteins, epigenetic regulation, KRAS gene, cancer-associated fibroblasts, tumor progression, drug resistance, immunotherapy resistance

A pivotal focus of this issue is the elucidation of cancer mechanisms, particularly the role of genetic mutations. Researchers have undertaken an extensive study analyzing a vast cohort of patient samples through advanced genomic sequencing techniques. This meticulous analysis has led to the identification of specific gene variants that significantly influence tumor growth and metastasis. The findings unveil the intricate molecular pathways that facilitate cancer progression, providing essential insights for the development of targeted therapies aimed at disrupting these aberrant biological processes.

The exploration of the tumor microenvironment reveals the complex interplay between cancer cells and their surroundings. In this issue, researchers highlight how elements of the microenvironment, including cancer-associated fibroblasts and various immune cells, interact in multifaceted ways with tumors. These interactions can either support or inhibit tumorigenesis, depending on the signaling molecules produced by the surrounding cells. The research emphasizes the importance of understanding these dynamics to formulate effective therapeutic strategies that can disrupt the supportive niche that cancer cells rely upon for survival and growth.

In a promising development within the field of cancer therapeutics, researchers present a novel approach to immunotherapy. By engineering immune cells to express specific receptors that target unique antigens found on cancer cells, the team has achieved heightened anti-tumor immune responses in preclinical models. This innovative strategy marks a significant advancement in immunotherapy, offering potential solutions to overcome challenges faced by existing treatments. By focusing on unique cancer-specific targets, this research paves the way for more effective cancer immunotherapy, with the hope of enhancing patient outcomes.

Complementing immunotherapy advancements, the issue also features a study exploring the synergistic effects of combining traditional chemotherapy with novel inhibitors. This dual approach has shown promise in amplifying the cytotoxic effects on cancer cells while concurrently minimizing the toxic side effects commonly associated with chemotherapy. The findings underscore the importance of collaborative treatment regimens that enhance the therapeutic efficacy while safeguarding patient health.

Early detection of cancer is crucial for successful intervention, and significant progress has been made in developing diagnostic tools. One highlighted research article presents a highly sensitive biomarker panel for early cancer detection. By integrating various biomarkers from diverse sources, including blood, tissues, and bodily fluids, this panel promises to improve detection accuracy compared to conventional methods. This innovative biomarker approach could facilitate earlier interventions and better outcomes for patients diagnosed with cancer by identifying the disease at its nascent stages.

This thematic issue also serves as a repository of comprehensive reviews summarizing current trends and breakthroughs in specific domains of cancer research. These reviews provide succinct yet thorough summaries of the advancements, acting as valuable resources for researchers and clinicians striving to stay at the forefront of cancer research and treatment. The collective knowledge shared within these articles highlights promising avenues for future investigations and therapeutic strategies.

The breadth of research compiled in this issue truly reflects the multidisciplinary approach necessary to tackle the complexities of cancer. It calls for a synergistic effort across genetic, biological, and clinical domains to devise nuanced solutions that address not only the disease but also its numerous facets—its biology, its behavior, and the host responses it elicits.

The advancements described herein are not confined to academic discourse; they possess profound implications for clinical practice, patient care, and the broader landscape of oncology. As researchers continue to decode the intricacies of cancer mechanisms and develop novel therapies, the ultimate goal remains clear: to improve outcomes for patients and enhance the quality of life for those affected by cancer.

This issue stands as a testament to the tireless efforts of scientists and healthcare professionals dedicated to combating cancer. Their collaborative work is driving the field forward and fueling hope for future breakthroughs that may finally tip the scales in favor of effective cancer prevention, treatment, and ultimately, eradication.

The studies and reviews published in this issue underscore the significant progress being made in understanding and treating cancer. As research progresses, each new discovery brings us one step closer to unlocking the mysteries of this complex disease. The insights presented herein promise to inform and inspire future research initiatives, thereby advancing our shared fight against cancer.

Subject of Research: Cancer mechanisms, therapeutic strategies, tumor microenvironment, and diagnostics.
Article Title: Not Provided
News Publication Date: Not Provided
Web References: Not Provided
References: Not Provided
Image Credits: Higher Education Press

Keywords: Cancer Research, Tumor Microenvironment, Genetic Mutations, Immunotherapy, Biomarkers, Chemotherapy, Oncology Advances.